



CS/NSE&BSE/UFR/2019-20
February 13, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....

With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 13th February, 2020, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results of the Company (Post Demerger) under Ind AS for the quarter and nine months ended 31st December, 2019.

We are enclosing herewith the following documents:

- a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter and nine months ended 31st December, 2019 and
- b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above

We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 14:40 P.M.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**


Shrenik Soni
Company Secretary

Encl: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com




SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Rs. In Lakhs

STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & 9 MONTHS PERIOD ENDED 31st Dec ' 2019.

PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 months period ended		For the year Ended
		31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
		un-Audited	un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	277.26	138.73	210.57	575.47	28,328.98	28,566.97
	Other Income	585.53	238.10	674.08	1,103.92	2,145.47	2,724.50
	Total income	862.79	376.83	884.65	1,679.39	30,474.45	31,291.47
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	7,961.69	7,961.69
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	(929.28)	(929.28)
	d) Employee benefits expense	242.29	420.11	631.42	1,111.35	3,273.19	3,384.64
	e) Finance costs	9.81	10.40	-	30.82	161.19	190.26
	f) Depreciation and amortisation expense	85.50	141.61	98.77	311.63	1,113.79	1,078.97
	g) Manufacturing Exps	-	-	-	-	4,825.55	4,870.09
	h) R & D Exps	638.55	751.18	839.88	2,018.11	4,240.71	5,936.86
	i) Other Expenses	332.57	217.89	107.50	764.61	2,157.30	2,472.86
	Total expenses	1,308.72	1,541.19	1,677.57	4,236.52	22,804.14	24,966.09
3	Profit before exceptional items & Tax (1-2)	(445.93)	(1,164.36)	(792.92)	(2,557.13)	7,670.31	6,325.38
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	(445.93)	(1,164.36)	(792.92)	(2,557.13)	7,670.31	6,325.38
6	Tax Expenses						
	a) Current tax	-	-	(165.85)	-	1,597.12	1,298.62
	b) Deferred tax	4.22	(41.11)	204.75	(1,438.16)	1,216.07	1,107.38
7	Net Profit/ (Loss) for the period/year(5-6)	(450.15)	(1,123.25)	(831.82)	(1,118.97)	4,857.12	3,919.38
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(14.41)	(1.06)	(10.58)	(16.53)	(31.75)	(21.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	5.04	0.37	3.77	5.78	11.09	7.39
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(9.37)	(0.69)	(6.81)	(10.75)	(20.66)	(13.77)
9	Total Comprehensive Income for the period (7+8)	(459.52)	(1,123.94)	(838.63)	(1,129.72)	4,836.46	3,905.61
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	-	-	38,899.39
12	Earning Per Share (EPS) (Face value of Rs. 1/- each) :						
	a) Basic	(0.35)	(0.88)	(0.65)	(0.88)	3.82	3.08
	b) Diluted	(0.35)	(0.88)	(0.65)	(0.88)	3.82	3.08
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	



PART - I		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 months period ended		For the year Ended
		31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
		un-Audited	un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	277.26	138.73	210.58	575.47	28,328.98	28,566.97
	Other Income	585.53	238.10	674.08	1,103.92	2,145.47	2,724.50
	Total income	862.79	376.83	884.66	1,679.39	30,474.45	31,291.47
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	7,961.69	7,961.69
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress	-	-	-	-	(929.28)	(929.27)
	d) Employee benefits expense	332.26	459.45	697.68	1,307.70	3,467.15	3,649.29
	e) Finance costs	10.21	10.80	-	31.91	161.93	191.33
	f) Depreciation and amortisation	85.50	141.61	98.77	311.63	1,113.79	1,078.97
	g) Manufacturing Exps	-	-	-	-	4,825.55	4,870.09
	h) R & D Exps	2,370.78	1,564.15	1,369.67	7,538.87	7,282.07	11,894.33
	i) Other Expenses	341.18	223.23	119.68	793.41	2,225.62	2,559.44
	Total expenses	3,139.93	2,399.24	2,285.80	9,983.52	26,108.52	31,275.87
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	(2,277.14)	(2,022.41)	(1,401.14)	(8,304.13)	4,365.93	15.60
4	Profit before exceptional items , Tax (3+4)	-	-	-	-	-	-
5	Exceptional Items	-	-	-	-	-	-
6	Profit before Tax (5-6)	(2,277.14)	(2,022.41)	(1,401.14)	(8,304.13)	4,365.93	15.60
7	Tax Expenses						
	a) Current tax	-	-	(165.85)	-	1,597.12	1,298.62
	b) Deferred tax	4.22	(41.11)	204.75	(1,438.16)	1,216.07	1,107.39
8	Net Profit/ (Loss) for the period/year(7-8)	(2,281.36)	(1,981.30)	(1,440.04)	(6,865.97)	1,552.74	(2,390.41)
9	Other Comprehensive Income						-
10.a	(i) Items that will not be reclassified to profit or loss	(14.41)	(1.05)	(10.58)	(16.52)	(31.75)	(21.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	5.03	0.37	3.77	5.77	11.10	7.39
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(9.38)	(0.68)	(6.81)	(10.75)	(20.65)	(13.77)
11	Total Comprehensive Income for the period (9 + 10)	(2,290.74)	(1,981.98)	(1,446.85)	(6,876.72)	1,532.09	(2,404.18)
12	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
13	Other Equity	-	-	-	-	-	22,640.16
14	Earning Per Share (EPS) (Face value of Rs. 1/- each) :						
	a) Basic	(1.79)	(1.56)	(1.13)	(5.39)	1.22	(1.88)
	b) Diluted	(1.79)	(1.56)	(1.13)	(5.39)	1.22	(1.88)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	



NOTES:-

1.The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 13th Feb 2020 and the same has been reviewed by the Statutory Auditors.

2.The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06,2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Company to Suvan Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date.

The impact of discontinued operations are as follows:

Parriculars	(Rs in Lakhs)					
	Quarter Ended 31.12.2019	Quarter Ended 30.09.2019	Quarter Ended 31.12.2018	For the 9 months Period Ended		Year Ended 31.03.2019
Total Income	18,359.37	27,837.28	12,710.09	66,180.25	12,710.09	37,843.47
Total Expenditure	11,182.17	15,696.76	8,396.01	37,265.19	8,396.01	22,056.76
Profit Before Tax	7,177.20	12,140.52	4,314.08	28,915.06	4,314.08	15,786.71
Tax Expense	1,977.35	3,148.94	868.95	7,231.11	868.95	4,859.28
Profit After Tax	5,199.85	8,991.58	3,445.13	21,683.95	3,445.13	10,927.43

Consequently, the figures in Column (5) & (6) represent Demerged Undertaking & Research and development Business for the period 01-04-2018 to 30-09-2018 (i.e PRE DEMERGER) and figures for the subsequent period 01-10-2018 to 31-12-2018 & 01-10-2018 to 31-03-2019 (POST DEMERGER) in Column (5) & (6) respectively are of Research and development Business as a result of demerger of CRAMS undertaking of the Company to Suvan Pharmaceuticals Limited (SPL) with effect from October 01, 2018. To that extent current quarter and nine months numbers are not comparable with previous periods presented.

3. The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

4. The Company is in the process of evaluating the impact of newly introduced Sec.115BAA of the Taxation Laws (Amendments) Ordinance, 2019.

5. The corresponding previous period figures have been regrouped / reclassified where ever necessary.

6.The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the websites of the stock exchanges(s) and the listed entity. (www.bseindia.com and www.nseindia.com) and company's website www.suven.com

Place : Hyderabad
Date : 13th Feb ' 2020



For SUVEN LIFE SCIENCES LTD

Venkata Jasti

VENKAT JASTI
Chairman & CEO
DIN: 00278028



Ref No.LR/SLSL/003/2019-20

Independent Auditor's Review Report on Unaudited Quarterly and Year to date Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **SUVEN LIFE SCIENCES LIMITED**, having registered office at 6th Floor, SDE Serene Chambers, Road No:5, Banjara Hills, Hyderabad-500034, Telangana for the quarter ended December 31, 2019 and year to date results for the period from April 01, 2019 to December 31, 2019 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation) as amended, read with SEBI Circular No. CIR/CFD/ CMD1/80/2019 dated July 19, 2019 ('the Circular').


This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial information/ financial results of USA branch included in the unaudited standalone financial results of the Company whose interim financial information/ financial results reflect total assets of Rs 163.65 lakhs as at 31st December, 2019 and total revenue of Rs.-Nil- for the period ended 31st December, 2019. The interim financial information/ financial results of this branch have been audited by the branch auditor, whose reports have been furnished to us, and our opinion in so far as it relates to the amounts and disclosures included in respect of these branches, is based solely on the report of such branch auditor. Our Conclusion is not modified in respect of this matter.

For **TUKARAM & CO LLP**
Chartered Accountants
(Firm Registration No.004436S)


(**RAJENDER REDDY K**)
PARTNER
M.No.231834
UDIN: 20231834AAAAAC9455



Place: Hyderabad
Date: February 13, 2020



Ref No.LR/SLSL004/2019-20

Independent Auditor's Review Report on the Unaudited Quarterly and Year to date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.


To
The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of SUVEN LIFE SCIENCES LIMITED ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended December 31, 2019 and year to date results for the period from April 01,2019 to December 31, 2019 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Regulation"), read with SEBI Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ("the Circular").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entity:

Name of the Company	Relationship
Suven Neuro Sciences Inc	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of branch auditor and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.



13/02/2020

6. We did not review the interim financial information/ financial results of USA branch of parent included in the unaudited standalone financial results of the Company whose interim financial information/ financial results reflect total assets of Rs 163.65 lakhs as at 31st December, 2019 and total revenue of Rs.-Nil- for the period ended 31st December, 2019. The interim financial information/ financial results of this branch have been audited by the branch auditor, whose reports have been furnished to us, and our opinion in so far as it relates to the amounts and disclosures included in respect of these branches, is based solely on the report of such branch auditor.


We did not review the interim financial information/ financial results of subsidiary included in the consolidated unaudited financial results, whose interim financial information/ financial results reflect total assets of Rs. 2,081.61 lakhs as at 31st December 2019, total revenue of Rs.Nil ,total expenses of Rs.5,747 lakhs and total net loss after tax of Rs. 5,747 lakhs for the period ended 31st December 2019, as considered in the consolidated unaudited financial results. These interim financial information/ financial results have been reviewed by other auditors, whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor.

Our conclusion on the Statement is not modified in respect of the above matters.

For **TUKARAM & CO LLP**
Chartered Accountants
(Firm Registration No.004436S)



(RAJENDER REDDY K)
P A R T N E R
M.No. 231834
UDIN: 20231834AAAAAD4339



Place: Hyderabad
Date : February 13, 2020

13/02/2020